uebhnb

Tag: Gentamycin Helicon Group Limited (ASX: HCG) is a pharmaceutical and healthcare company with an innovative strategy, listed on the Australian Securities Exchange. Its business is to identify and exploit niche market opportunities in the specialty pharmaceutical and healthcare markets of China and North Asia and to participate in the significant growth that has been projected for those markets over the next 20 years.Helicon identifies significant niche product opportunities for advanced, patented, US FDA approved or CE Mark western pharmaceutical and healthcare products that are not being adequately met in China and secures exclusive rights to such products that meet specific selection criteria. Helicon uses a low operating cost base in combination with established channel partners for product registration, marketing and sales.Volplex(R) is a gelatine based blood plasma substitute used in cases of trauma and/or after surgery. It is given by intravenous infusion in hospitals as it is well tolerated, sterile and does not interfere with blood coagulation. Helicon has secured the commercialisation rights for Volplexv in China and the South Korean markets. Due to inadequate infection control systems in China, the Chinese government has restricted blood donation programs, thus creating a growing demand for blood plasma substitutes where the risk of cross infection is insignificant.Collatamp(R) G is an implantable collagen sponge that is impregnated with the broad spectrum antibiotic, Gentamycin. In controlled clinical trials the device has been shown to significantly reduce the incidence of severe post surgical infections. The main benefit of this localised drug delivery system is that it ensures that high concentrations of the drug can be maintained onsite whilst avoiding the risk of systemic toxicity and the associated side effects of Gentamycin. Helicon has secured the exclusive product rights for China which has relatively high rates of post surgical site infections. ReCell(R) is a leading edge tissue engineering technology, developed by Clinical Professor Fiona Wood, FRCS, FRACS, AM, which revolves around the use of a patient's own skin cells to produce fresh skin in areas where trauma has occurred thereby significantly improving the likelihood of matching healthy skin and eliminating tissue rejection.It is utilised in the treatment of burns, small wounds, vitiligo, encouraging scar free healing and re-pigmentation. There is no other product able to match ReCell(R) on the international market, thus making it an ideal fit with Helicon's high end positioning. Helicon has the exclusive rights for China and Hong Kong and Macau. MedWrap(TM) Island Wound Dressing with Microban(R) contains a potent bacteriostatic agent indicated for surgical site infections. It is used for the management and control of post surgical site infections, enabling speedier patient recovery times. Helicon has secured the exclusive rights to this technology for China and a number of other Asian markets. Medwrap(TM) will be especially pertinent in the Chinese market where instances of surgical site infections are relatively high.
 2008-05-23 16:26:57